Skip to Main Content
Main Content

Medicare Drug Spending Dashboard


Medicare Drug Spending Dashboard

As part of its effort to provide additional information, increase transparency, and address the affordability of prescription drugs, CMS is releasing a new online dashboard to look at Medicare prescription drugs for both Part B and Part D. These categories include drugs with high spending on a per user basis, high spending for the program overall, and those with high unit cost increases in recent years.

To create this list, CMS identified 80 drugs using 2014 data that met the criteria described below, 40 drugs provided through the Medicare Prescription Drug Program under Part D and 40 drugs administered by physicians and other professionals in the Medicare fee-for-service program under Part B. Products have been selected from each respective program area based on the following criteria: the drug is ranked in the top 15 in terms of total program spending (for either Part B or D); the drug is associated with a high annual per user spending based on claims data analyses (e.g., greater than $10,000 per user) and is ranked in the top 15 by overall program spending (if a drug already is selected based on (a) it is not eligible to be selected based on (b) criteria); or the drug is ranked among the top 10 high unit cost increases (if a drug already is selected based on (a) or (b) it is not eligible to be selected based on (c) criteria).

For all drugs included, the tool displays relevant spending, utilization, and trend data and also includes consumer-friendly information on the drug product descriptions, manufacturer(s), and uses. CMS is prohibited from publicly disclosing information on manufacturer rebates thus the data used to select Part D drugs do not reflect any manufacturers’ rebates or other price concessions.  For additional information on the selection criteria, please see the detailed methodology document available via the link below.

 

Medicare Drug Spending Dashboard Evidence-based Practice Center (EPC) Reports Overview and Highlights


Access the Detailed Methodology Document here.

Download the full underlying data in Excel here.

Inquiries regarding this data can be sent to DrugListInput@cms.hhs.gov